Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Optimistic About 2020 Despite COVID-19 Impacts

May 01 2020

• By Mandy Jackson

Q1 1st First Quarter Period Stock Market Ticker Words 3d Illustration — Amgen's $6.2bn in Q1 revenue exceeded analyst consensus of $6bn • Source: Shutterstock

Related Content

Amgen KRAS Inhibitor Less Effective In Colorectal Cancer Than Lung

Sep 28 2019

Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake

Nov 01 2019

Amgen To Buy Out Japan JV With Astellas

Jan 23 2020

Amgen's $13.4bn Otezla Buy Helps Bristol/Celgene Merger Close By Year-End

Aug 27 2019

Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines

Jan 31 2020

A Rocky First Quarter For Big Pharma Stocks

Apr 16 2020

Merck Cuts Pharma Revenue Guidance By $1.7bn Due To Pandemic

Apr 28 2020

Related Companies

Amgen, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

Astellas Pharma, Inc.

BeOne Medicines Ltd.

Additional Topics

Sales & Earnings Business Strategies Coronavirus COVID-19 Companies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window